case_images: PMC3671292_01
case_images: Left sided T1aN0M0 vocal cord carcinoma under surgical microscope.
case_images: CRIM.PULMONOLOGY2013-308092.001.jpg
case_images: PMC3671292_01_CRIM.PULMONOLOGY2013-308092.001.jpg
case_images: fig1
case_images: Within a year her voice turned increasingly hoarse and a second larynx carcinoma on the opposite vocal cord was discovered (Figure 1).
case_images: HRCT of the thorax after discontinuation of infliximab showing increased consolidation and nodular abnormalities.
case_images: CRIM.PULMONOLOGY2013-308092.002.jpg
case_images: PMC3671292_01_CRIM.PULMONOLOGY2013-308092.002.jpg
case_images: fig2
case_images: Unfortunately, half a year after infliximab discontinuation the small fiber neuropathy and pulmonary symptoms returned as shown on High Resolution CT of the chest (Figure 2) and on 18-FDG-PET scan which revealed extensive systemic reactivation of sarcoidosis (Figure 3).
case_images: 18F-FDG-PET scan monitoring sarcoidosis activity level. In the left frame is shown the 18F-FDG-PET scan during treatment with infliximab and in the right frame the 18F-FDG-PET scan after discontinuation of infliximab revealing reactivation of sarcoidosis as black spots in lungs and lymph nodes.
case_images: CRIM.PULMONOLOGY2013-308092.003.jpg
case_images: PMC3671292_01_CRIM.PULMONOLOGY2013-308092.003.jpg
case_images: fig3
case_images: Unfortunately, half a year after infliximab discontinuation the small fiber neuropathy and pulmonary symptoms returned as shown on High Resolution CT of the chest (Figure 2) and on 18-FDG-PET scan which revealed extensive systemic reactivation of sarcoidosis (Figure 3).